Head to head
Efruxifermin against Semaglutide
Two different bets on metabolic liver disease, one working through an FGF21 pathway and one through weight loss. Both have fibrosis or liver fat data; neither has been randomised against the other, and neither has shown a reduction in cirrhosis, transplant or death.
Column A
EfruxiferminEfruxifermin (EFX, AKR-001)
A weekly FGF21 analog that missed its 36-week primary endpoint in compensated MASH cirrhosis but improved fibrosis in 29% of patients by 96 weeks against 11% on placebo, with three Phase 3 SYNCHRONY trials under way.
Column B
SemaglutideSemaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Side by side, on the facts we can check
| Attribute | Efruxifermin | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational; Phase 3 | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | Weekly subcutaneous dosing | ~7 days |
| Molecular weight | 92,108 Da (Fc-FGF21 fusion protein) | 4,113.6 Da |
| Mechanism | Long-acting FGF21 receptor agonism (FGFR1c/beta-klotho) that lowers liver fat, improves insulin sensitivity and reduces fibrosis. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Human studies cited | 2 | 5 |
| Legal status, US | Investigational, not approved | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Efruxifermin and Semaglutide?
Efruxifermin: A weekly FGF21 analog that missed its 36-week primary endpoint in compensated MASH cirrhosis but improved fibrosis in 29% of patients by 96 weeks against 11% on placebo, with three Phase 3 SYNCHRONY trials under way. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Efruxifermin or Semaglutide?
This database does not grade compounds. It counts what was run in people: 2 of the 2 studies cited on the Efruxifermin profile were human work, against 5 of 5 for Semaglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Efruxifermin and Semaglutide FDA-approved?
Efruxifermin: Investigational; Phase 3. Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Related posts
Blog articles that cover Efruxifermin or Semaglutide, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 8 minTesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue
- Longevity / Sep 8, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Metabolic / Sep 8, 2026 / 10 minOral GLP-1s in 2026: Wegovy Pill vs Foundayo (Orforglipron) vs Rybelsus, and What Is Coming
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.